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Abstract
Background: Most HIV treatment programs in resource-limited settings utilize multiple facilitators of adherence and
retention in care but there is little data on the efficacy of these methods. We performed an observational cohort analysis of
a treatment program in Kenya to assess which program components promote adherence and retention in HIV care in East
Africa.
Methods: Patients initiating ART at A.I.C. Kijabe Hospital were prospectively enrolled in an observational study. Kijabe has an
intensive program to promote adherence and retention in care during the first 6 months of ART that incorporates the
following facilitators: home visits by community health workers, community based support groups, pharmacy counseling,
and unannounced pill counts by clinicians. The primary endpoint was time to treatment failure, defined as a detectable HIV-
1 viral load; discontinuation of ART; death; or loss to follow-up. Time to treatment failure for each facilitator was calculated
using Kaplan-Meier analysis. The relative effects of the facilitators were determined by the Cox Proportional Hazards Model.
Results: 301 patients were enrolled. Time to treatment failure was longer in patients participating in support groups (448
days vs. 337 days, P,0.001), pharmacy counseling (480 days vs. 386 days, P=0.002), pill counts (482 days vs. 189 days,
P,0.001) and home visits (485 days vs. 426 days, P=0.024). Better adherence was seen with support groups (89% vs. 82%,
P=0.05) and pill counts (89% vs. 75%, P=0.02). Multivariate analysis using the Cox Model found significant reductions in risk
of treatment failure associated with pill counts (HR=0.19, P,0.001) and support groups (HR=0.43, P=0.003).
Conclusion: Unannounced pill counts by the clinician and community based support groups were associated with better
long term treatment success and with better adherence.
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Introduction
The roll out of anti-retroviral therapy in resource-limited setting
has resulted in millions of individuals now receiving life saving
therapy [1]. The U.S. Presidents Emergency Plan for AIDS Relief
was initially envisioned as an emergency response to a humani-
tarian crisis. As anti-retroviral medications are reaching increasing
numbers of HIV infected persons, the focus of this program has
shifted to sustaining these efforts [2]. Sustainability of systems of
HIV care has many facets but retention in care and adherence to
anti-retroviral medication are critical to the maintenance of these
endeavors.
There is a need to identify effective methods to retain patients in
care and promote adherence to HIV regimens [3–6]. A recent
meta-analysis of published reports found that only 60% of patients
started on anti-retroviral drugs remained on therapy after 2 years
[4]. Identification of approaches that optimize adherence to
therapy remains a key challenge [7]. Data from developed
countries have shown that missing 10% to 15% of doses of anti-
retroviral drugs is linked to incomplete suppression of viral
replication, declining CD4 cell counts, progression to AIDS, and
the emergence of antiretroviral drug resistance [8,9].
In sub-Saharan Africa, a number of evidence based interven-
tions to retain patients in care and to foster adherence to HIV
medications have been reported [10–20]. These interventions
were designed to address stigma, isolation, lack of community
support and poor health literacy, all of which have all been shown
to contribute to poor adherence retention into care. Community
based programs are widely used to support patients in taking anti-
retroviral drugs, encourage attendance at clinics and to find
treatment defaulters [11,12,14,18,20]. Intensive patient education
by community health workers, pharmacists and clinical care
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‘‘Real Time’’ monitoring of pill taking by clinicians and
pharmacists can also identify individuals with adherence difficul-
ties that may require additional counseling [10,14,21]. [1] Most
program evaluations are uni-dimensional and do not examine the
overlapping effect of the multiple approaches to improve retention
into care and anti-retroviral adherence. Similarly, many studies
focus on a single endpoint and do not evaluate other important
outcomes such as retention in the program, virologic success and
survival. Etienne et al studied a tiered approach to retention in
care and adherence in 27 countries and found that those centers
that utilized community programs, intensive adherence education
and active monitoring of pill taking had the best results when
compared to centers that only offered basic patient education [22].
We performed a prospective, observational cohort analysis of a
single medical center that utilizes tiered approach retention in care
and adherence promotion [22]. As a precondition to participation
into the program, patients agree to participate all of the treatment
and adherence activities. In reality, many patients only participate
in some, allowing for an evaluation of the relative, individual
contribution of each of the interventions on the long-term patient
outcomes through a multivariate analysis. Thus we can identify the
most effective, easily scalable, practices that will support
sustainability of the anti-retroviral effort in resource limited
settings.
Methods
Study Setting
AIC Kijabe Hospital is a 265 bed hospital located 60 kilometers
northwest of Nairobi, Kenya. It follows approximately 6000
patients on anti-retroviral therapy at six locations in Central
Kenya. Kenya utilizes a catchment system of care for HIV patients
and thus only those who live within a 40 km radius of the hospital
are eligible for enrollment into the treatment program. The
program utilizes a wide array of personnel to provide care that
include consultant physicians, medical officers and clinical officers.
Nurses assist in care in the clinics and coordinate community
health workers. A community heath program using nurses and
community health workers acts as a liaison between the clinics and
the patients and manages community-based facilitators of
adherence and retention into care. All medications are dispensed
by the Kijabe pharmacy by a pharmacist. Medical records are
abstracted and entered into an electronic database.
The Kijabe HIV program utilizes the highest tiered approach to
facilitate adherence and promote retention into care described by
Etienne et. al. A schematic of the treatment program and of the
study are shown in Figure 1. The nature of adherence support and
training of staff are described in the prior publication. [22]. During
the first six months of HIV therapy, patients must agree to
participate in all adherence activities as a condition for receiving
medication. Specific elements of the program include:
Treatment Preparation Classes
Patients learn about HIV infection, treatment, the importance
of adherence and of programmatic requirements. There are three
required classes over 3 weeks, each lasting about one hour.
Treatment Buddy
Patients are required to identify a treatment buddy who is
typically someone who has already been in treatment to encourage
and assist with medication adherence.
Treatment Contract
Patients sign a contract agreeing to participate in both the
community program and in the medical care provided by the
program.
Figure 1. Schematic Diagram of HIV Program and Observational Study Design. The HIV program is divided into 3 distinct activities, HIV
testing, Treatment Preparation, and Antiretroviral treatment that includes both community and clinic based facilitators. For entry into the study,
subjects must be HIV positive and complete all treatment preparation activities. The study period begins with initiation of ART and evaluates the
effects of treatment facilitators on treatment success.
doi:10.1371/journal.pone.0032727.g001
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1. Home Visits. Within one month of initiating ART,
community health workers visit patients in their homes and
assess barriers to care, patient adherence to medication and
overall health status. Patients are referred back to the clinic if
acute medical problems are encountered. Repeat visits are
scheduled each month as need.
2. Support Groups Meetings. Support group meetings are
held monthly in each of the six local communities where there
are clinic sites. Meetings are typically held in local churches.
Community health workers organize the support group. Patients
attend with their treatment buddies. There are open discussions
of both problems and successes associated with HIV therapy.
Medical Care
Patients must come to the clinic on a monthly basis for the first
six months. They undergo a medical evaluation by their care
provider.
1. Unannounced Pill Counts. Patient providers count pills to
assess their adherence and to provide a context for adherence
counseling.
2. Pharmacy Counseling. After the care provider visit, the
patient meets with a pharmacist to discuss any difficulties in
taking medication and to further address adherence issues
discovered during the provider visits.
Participants
Study participants were recruited from AIC Kijabe Hospital’s
HIV Program.
Eligibility requirements for the study were:
1. HIV positive by Kenyan National AIDS and STI Control
Program Criteria.
2. Age greater than 18 years old.
3. Anti-retroviral naı ¨ve with the exception of women who had
previously received medication as part of prevention of mother
to child transmission.
4. Completion of anti-retroviral treatment preparation course.
5. Identification of a Treatment buddy.
6. Signed treatment contract.
7. Providing informed consent.
Ethics
This study was approved by the A.I.C. (African Inland Church)
Kijabe Hospital Ethics Board, and the Kenya Medical Research
Institute National Ethics Committee and the University of Texas
Medical Branch Institutional Review Board. All subjects provided
written informed consent prior enrollment into the study. Consent
forms were available in both English and Swahili. For subjects who
could not read either language, the consent form was explained to
them by native speakers in their mother tongues.
Study Design/Intervention
This was a prospective, observational cohort study that did not
involve an intervention.
Objectives
The objective of this study was to compare the relative effect of
participation in ongoing facilitators of retention into care and
adherence that occur after treatment initiation on time to
treatment failure. Specific facilitators evaluated were:
N Home visits
N Support Groups Meetings
N Pharmacy Counseling
N Un-announced Pill Counts
Outcomes
The primary outcome was defined as time to treatment failure
from date of initiation of anti-retroviral medication. Treatment
failure was defined as any one of the following:
1. Virologic failure: defined as failure to achieve an HIV-1 RNA
less than 200 copies/ml at 6 months or an HIV-1 RNA greater
than 200 copies/ml at one year after achieving an undetectable
viral load.
2. Lost to Follow Up: Defined as not appearing for any treatment
program activities for 90 days and inability of the community
health workers to find the subject.
3. Discontinuation of Therapy: Defined as not picking up
prescriptions for ninety days.
4. Death: verified by clinical personnel or by community health
workers performing home visits.
Data Collection
Participants were followed for one year after initiation of ART.
Data was primarily collected from the patient medical record.
Demographic data was collected from participant charts at
baseline. CD4 counts were performed at initiation of therapy
following standard of care. Viral loads were measured on study
participants at baseline, 6 months, and 12 months. Data was
managed using Microsoft Access. Dispensation of anti-retroviral
drugs was collected from months 1 to 12. Participation in each of
the key activities of the study was collected at each month.
Kijabe utilizes patient treatment logs for both clinical and
administrative purposes and these were used to confirm patient
participation in study activities. All participants in support groups
were required to sign an attendance sheet at the beginning of each
meeting. Confirmation of home visits was confirmed by reviewing
travel receipts for community health workers. Pharmacists confirm
counseling visits in the dispensation record. Pill counts were solely
recorded in the clinic record at the time the patient was seen by
the clinician.
Laboratory Methods
Blood samples were drawn from participants at baseline, 6
months, and 12 months. Serum was separated and stored in a 280
freezer for batched HIV-1 RNA testing. HIV-1 RNA testing was
performed at AIC Kijabe Hospital using the ExaVir HIV-1 RT
assay (Cavidi, Uppsala Sweden). This is an HIV-1 RT assay that
correlates well with standard HIV-1 PCR and is widely used in
resource-limited setting [23]. Samples were stored in a 220 freezer
until they could be run in batches. HIV CD4 testing was
performed using FACSCount (BD, UK).
Sample Size
Preliminary data from a quality improvement project per-
formed in 2008 found that 85% of HIV positive adults at Kijabe
who had been on anti-retroviral therapy from 9–18 months had an
undetectable HIV-1 viral load. The same study found a drop out
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therapy. From this data, we assumed that 25% of subjects would
be treatment failures in our study. Based on this, 280 subjects
would provide an 80% power at a significance level of 0.05 when 5
independent variables are included; corresponding to an odds
ratio of 2.5.
Statistical Analysis
The primary endpoint was time to clinical failure. Failure was
defined as being lost to follow-up, death, or having a detectable
viral load at the end of study follow-up. The relationship between
each patient activity and treatment success or failure was evaluated
using Pearson’s CHI squared test, Fishers exact test or student t
test where appropriate. Adherence to medication was collected by
review of pharmacy refill records for each participant using the
method described by El-Khatib [24]. Time to failure was modeled
using Kaplan-Meier plots.
The effects of participation in study activities on treatment
failure were compared in two ways: first as a (Yes/No) and then a
cut point between the differences in the medians between of
treatment successes and failures. Those factors that were
statistically significant (P,0.05) were further evaluated by
comparing time to treatment failure. Significant differences
between treatment failure and success were further evaluated
using Cox Proportional Hazard regression models. The level of
statistical significance utilized was p,0.05
Results
Participant Flow is shown in Table 1. Subjects were enrolled
between November 1, 2009 and April 20, 2010. There were 351
subjects screened. Of these 50 (14%) were ineligible because of
age, prior ART or a subsequent negative HIV test. This latter
group is of interest because all came to the study with reports of
positive HIV test. Repeat HIV testing were negative in all of these
including a negative HIV viral load. There were 301 subjects
enrolled. Of these, 10 transferred out of care and their data was
censored. Of the remaining 291 subjects, 85 (29%) were treatment
failures and 206 were treatment successes. Only 40% of subjects
participated in all of the required adherence activities.
Table 2 compares the baseline characteristics between the
treatment successes and treatment failures. There were no
differences between the groups with regard to age at initiation of
therapy, baseline CD4 cell counts, baseline viral load, employment
status or distance to clinic. Treatment successes were more likely to
be female (74% vs. 61%, P=0.027, Pearsons Chi square test).
Adherence as measured by pharmacy refill history was better in
the treatment successes than the failures (90% vs. 82%, P=0.043,
Pearsons Chi square test). Successes were more likely to attend
support group meetings (median 3 vs. 2, P=0.001, Fisher’s exact
test), to have pharmacy counseling (median 2 vs. 1, P=0.01,
Fisher’s exact test), to have a pill count performed by their
clinician at a clinic visit (median 4 vs. 3, P=0.001, Fisher’s exact
test) and to have attended all six of their clinic visits within the first
6 months of therapy (median 6 vs. 5, P=0.001, Fisher’s exact test).
There was no difference in the median number of home visits
between treatment successes and failures.
Figure 2 compares the percent adherence between the
treatment successes and failures by median number of patient
activities. The cut points for each of the interventions were based
on the medians shown in Table 2. Adherence was significantly
higher in those who participated in 3 or more support group
meetings (90% vs. 83%, P,0.05), who had pill counts performed
by their clinician (90% vs. 76%, P=0.001, and who attended all
clinic visits (90% vs. 72% P=0.001). Homes visits and pharmacy
counseling were not associated with differences in adherence.
Time to treatment failure is shown in Figure 3. There was a
significantly shortened time to treatment failure associated with
having home visits (463 days vs. 394 days), having four or more pill
counts by their provider (481 days vs. 355 days), participating in
three or more support groups (480 days vs. 425 days), and
participating in 2 or more pharmacy counseling sessions (461 days
vs. 338 days). Each of these comparisons were statistically
significant with P,0.05 by log-rank test.) However, when time
to treatment failure was analyzed based on whether subjects had
ever participated in any of the adherence activities (yes vs. no) only
participation support groups, ever having a pill count performed
or completing all six clinic visits were statistically significant. We
analyzed the whether the total number of activities that the
subjects participated in was predictive of outcome but could find
no significant associations.
Table 1. Participant Flow and Outcomes.
N( % )
Patients Screened 351 (100)
Ineligible 50
Negative HIV Test 13
Prior ART 3
Age,13 34
Enrolled 301
Outcomes
Virologic Failure 48 (15.9)
Dead 15 (5)
Lost to Follow Up 22 (7.3)
Transferred Out 10 (3.3)
Treatment Success 206 (68.4)
doi:10.1371/journal.pone.0032727.t001
Table 2. Comparisons of Treatment Success and Failures.
Factors
Success
(N=206)
Failures
(N=85) P Value
Age (mean) 37 37 0.97
CD4 Count (mean) 170 cells/mm3 170 cells/mm3 0.97
Viral Load (mean log10) 4.44 4.57 0.28
Female (%) 74% 61% 0.027
Unemployed (%) 43% 40% 0.58
Distance from Clinic (mean) 14.2 km 13.7 km 0.78
Adherence (mean) 90% 82% 0.043
Interventions (median)
Home Visits 1 1 0.096
Support Groups 3 2 0.001
Pill Counts 4 3 0.001
Post Pharmacy Counseling 2 1 0.013
Clinic Visits 6 5 0.001
Total Number of Facilitators 5 4 0.083
doi:10.1371/journal.pone.0032727.t002
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Cox Proportional Hazards model is shown in Table 3. The
baseline characteristics that were considered for inclusion into the
model are listed in paragraph one and in Table 2. In addition, we
also tested CD4 cell count, log of viral model as these have been
previously shown to affect time to failure. In the multivariate
analysis, CD4 and viral load were not significant and were not
significant in comparison of baseline differences in outcomes and
were ultimately not included in the model. Tests of co-linearity
between clinic visits, pill counts, and pharmacy visits were not
significant (p.0.05 for all comparisons) On multivariate analysis,
there was a significant reduction in risk of failure with completion
of all clinic visits (HR=0.46, p=0.003), participation in 3 or more
support groups (HR=0.54, p=0.014) and having 4 or more pill
counts performed by the subjects clinicians (HR=0.57, p=0.026).
Discussion
There is an urgent need to identify effective facilitators of
adherence and retention to care in resource limited settings.
Observational studies can help identify potentially effective means
of promoting successful treatment outcomes and can direct future
investigations. Many studies are retrospective and/or use retention
in care as the primary endpoint [3–6,15,25–27]. The high lost to
follow up rates in such analysis had led to the call for better
methods to assess vital status in resource limited settings [28–30].
In this study, we sought to determine the elements of a treatment
program that were associated with successful HIV care. The
setting for the study included both community and hospital based
activities and utilized multiple, evidence based interventions to
promote adherence to HIV care. Although subjects agreed to
participate in all of these activities as a precondition to entry, only
40% of subjects were 100 percent compliant, thus allowing for an
evaluation of the relative, individual contribution of each of the
interventions on the long-term patient outcomes through a
multivariate analysis. The prospective nature of this analysis
meant that we were able to account for all but seven percent of the
patients who enrolled in the study, a percentage that is significantly
lower than reported in other studies. Our use of multiple viral load
tests allowed for earlier recognition of failure of anti-retroviral
medications. Had we solely relied on CD4 count declines, it may
have taken several years before individuals had reached a clinical
endpoint. Of the facilitators evaluated, we found participation in
community based support groups, and unannounced pill counts
performed by the patients care provider in front of the patient
were associated with improved adherence and decreased risks of
treatment failure. We also found that women were more likely to
be successfully retained in care and treated, a finding that has been
seen in other studies [16].
A significant finding of this study is that pill counts were
associated with better treatment outcomes. Although pill counts
have been widely studied as tool to measure adherence, there has
been little evaluation of their use as facilitators of adherence. In
our study, we examined only whether a pill count was performed
Figure 2. Rates of Adherence Categorized by Interventions. Rates of adherence in treatment successes and failures is shown by each
intervention: 1) greater than one home visit; 2) participation in two or more support groups; 3) having four or more unannounced pill counts by
primary care provider; 4) having two or more counseling sessions by a pharmacist; 5) completing six or more clinic visits.
doi:10.1371/journal.pone.0032727.g002
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found that the number of times a pill count was performed as
associated with both better adherence and better treatment
outcomes, suggesting that intermittent pill counts may have a
motivational effect on patients that result in better outcomes. In
addition, pill counts are easy to perform, do not require special
technology and are easily implemented across a wide spectrum of
settings.
Our data has important implications for future research and for
allocation of both clinical and research resources. Performance of
pill counts by the clinician would seem to be a relatively easy and
effective method for promoting adherence. Community based
support groups require planning, personnel and travel, but also
have a demonstrated clinical benefit. On the other hand,
counseling by a pharmacist was not associated with clinical
benefit nor did regular home visits seem to improve outcomes.
The pharmacy counseling requires the time of a pharmacist and
home visits require both community health workers time and
travel. It may be that these interventions are not necessary for
routine patient care and are best targeted for patients who have
specific needs.
The results must be interpreted with caution. The study design
is observational and thus there is potential for un-measured biases
that could affect the outcome. An underlying assumption of the
study was that each of the facilitators evaluated were independent
predictors of treatment outcome. We were able to demonstrate
associations between these interventions and did not find any
interaction between significant facilitators on multivariate analysis.
There was also no association between the total number of
facilitators that subjects participated in and outcome, suggesting
Figure 3. Time to Treatment Failure Categorized by Interventions. Kaplan Meier plots of time to treatment failure stratified by: A)
participation in two or more support group meetings; B) having four or more unannounced pill counts by primary care provider; C) at least one home
visit; D) having two or more counseling sessions by a pharmacist.
doi:10.1371/journal.pone.0032727.g003
Table 3. Multivariate Analysis of Risk of Failure.
Factor Risk P
$6 clinic visits 0.46 0.003
$3 Support Groups 0.54 0.014
$4 Pill Counts 0.57 0.026
Female Gender 0.62 0.034
(Cox Proportional Hazards Model). P.0.05 for interactions.
doi:10.1371/journal.pone.0032727.t003
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not to the total system of care. In addition, the study was
performed within a single organization with multiple sites in rural
Kenya and it is not clear how generalizable the results would be to
other systems of care in other settings. We also did not perform a
cost benefit analysis hence any discussion of cost effectiveness of
the interventions would be speculative.
However, statistical associations do not demonstrate causality
and further evaluations of our findings are warranted. The best
way to evaluate the effectiveness of these interventions would be
with a cluster-randomized trial using multiple sites. In such a
design, one site would perform pill counts, another would perform
have support groups in the community setting and a third would
perform post clinic pharmacy counseling. The effect on clinical
failure of each intervention would be determined. This would also
allow for qualitative and quantitative assessments of the social,
cultural and spiritual influencers on adherence and test interven-
tions to address those influencers on the markers of failure and
success.
A formal cost analysis could also be performed and the cost
benefit of each intervention could be determined. Such a strategy
would allow for the identification of the most cost effective
interventions that could then be replicated in other settings.
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